Pro Medicus Ltd (ASX: PME) shares have dropped more than 20% since their peak a few weeks ago. Is this an opportunity to buy?

Wasatch International Growth Fund—Investor Class was down -7.22% but outperformed MSCI AC (All Country) World ex USA Small ...

Morgans analyst Scott Power notes there's a risk-off sentiment among investors as ASX health stocks fall again this week.

First Sentier’s David Wilson & Christian Guerra on 2025’s volatile reporting season, market surprises & top growth stock ...

These top ASX shares could be great picks for investors with $3,000 to put into the share market. Let's find out ...

The deepening market sell off has not spared many of the big commercialised, profitable biotechs. But the question is whether ...

Healthcare duo Pro Medicus and Sigma Healthcare will join the ASX 50 index later this month, while mining group Mineral ...

Bei Liu made waves by leaving Tribeca after 20 years — taking the Alpha Plus fund with her. She shares why she made the move ...

USA-based Medicus Pharma has announced a positive-trending interim analysis for the SKNJCT-003 Phase II study, which aims to treat non-invasively basal cell carcinoma of the skin (BCC).

Medicus Pharma (MDCX) announces a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell ...

Currently, Visage 7 is limited to radiology departments, but Pro Medicus is aiming to extend the product set to other ...